FK506 affects mitochondrial protein synthesis and oxygen consumption in human cells

Author: Palacín María   Coto Eliecer   Llobet Laura   Pacheu-Grau David   Montoya Julio   Ruiz-Pesini Eduardo  

Publisher: Springer Publishing Company

ISSN: 0742-2091

Source: Cell Biology and Toxicology, Vol.29, Iss.6, 2013-12, pp. : 407-414

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

FK506 is an important immunosuppressive medication. However, it can provoke neurotoxicity, nephrotoxicity, and diabetes as adverse side effects. The decrease in oxygen consumption of rat cells treated with pharmacologically relevant concentrations of FK506, along with other evidences, has insinuated that some of the toxic effects are probably caused by drug-induced mitochondrial dysfunction at the level of gene expression. To confirm this suggestion, we have analyzed cell respiration and mitochondrial protein synthesis in human cell lines treated with FK506. This drug provokes an important decrease in oxygen consumption, accompanied by a slight reduction in the synthesis of mitochondria DNA-encoded proteins. These results are similar to those triggered by rapamycin, another macrolide with immunosuppressive properties, therefore insinuating a common toxic pathway.

Related content